• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.

作者信息

Chang Jun, Zou Shaoqing, Xiao Yiwen, Zhu Du

机构信息

College of Life Science, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi, China.

出版信息

BMC Complement Med Ther. 2024 Aug 21;24(1):312. doi: 10.1186/s12906-024-04616-w.

DOI:10.1186/s12906-024-04616-w
PMID:39169345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11340049/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b91/11340049/bd07fff9545f/12906_2024_4616_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b91/11340049/bd07fff9545f/12906_2024_4616_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b91/11340049/bd07fff9545f/12906_2024_4616_Fig1_HTML.jpg

相似文献

1
Correction: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.更正：通过基于生物信息学和分子对接的方法鉴定和验证獐牙菜苦苷对特发性肺纤维化的靶点
BMC Complement Med Ther. 2024 Aug 21;24(1):312. doi: 10.1186/s12906-024-04616-w.
2
Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.通过生物信息学和分子对接方法鉴定和验证獐牙菜苦苷治疗特发性肺纤维化的作用靶点。
BMC Complement Med Ther. 2023 Oct 5;23(1):352. doi: 10.1186/s12906-023-04171-w.
3
Screening of Inhibitors against Idiopathic Pulmonary Fibrosis: Few-shot Machine Learning and Molecule Docking based Drug Repurposing.特发性肺纤维化抑制剂的筛选：基于少样本机器学习和分子对接的药物重定位。
Curr Comput Aided Drug Des. 2024;20(2):134-144. doi: 10.2174/1573409919666230417080832.
4
Molecular docking, antiproliferative and anticonvulsant activities of swertiamarin isolated from Enicostemma axillare.从肾茶中分离得到的当药苦苷的分子对接、抗增殖和抗惊厥活性。
Bioorg Chem. 2020 Jan;94:103428. doi: 10.1016/j.bioorg.2019.103428. Epub 2019 Nov 8.
5
Exploring the potential of semi-synthetic Swertiamarin analogues for GLUT facilitation and insulin secretion in NIT-1 cell lines: a molecular docking and study.探索半合成獐牙菜苦苷类似物在NIT-1细胞系中促进葡萄糖转运蛋白（GLUT）和胰岛素分泌的潜力：分子对接及研究
Nat Prod Res. 2024 Apr 15:1-5. doi: 10.1080/14786419.2024.2342005.
6
Bioinformatics analysis of differentially expressed genes in hepatocellular carcinoma cells exposed to Swertiamarin.獐牙菜苦苷处理的肝癌细胞中差异表达基因的生物信息学分析
J Cancer. 2019 Oct 21;10(26):6526-6534. doi: 10.7150/jca.33666. eCollection 2019.
7
Deciphering the Underlying Mechanisms of Sanleng-Ezhu for the Treatment of Idiopathic Pulmonary Fibrosis Based on Network Pharmacology and Single-cell RNA Sequencing Data.基于网络药理学和单细胞 RNA 测序数据解析三楞莪术治疗特发性肺纤维化的潜在机制。
Curr Comput Aided Drug Des. 2024;20(6):888-910. doi: 10.2174/1573409920666230808120504.
8
and screening of novel typhoid drugs from endangered herb ().从濒危草药中筛选新型伤寒药物。
J Biomol Struct Dyn. 2023 Apr;41(7):2926-2936. doi: 10.1080/07391102.2022.2041488. Epub 2022 Feb 17.
9
The molecular mechanism of Ligusticum wallichii for improving idiopathic pulmonary fibrosis: A network pharmacology and molecular docking study.当归改善特发性肺纤维化的分子机制：网络药理学和分子对接研究。
Medicine (Baltimore). 2022 Feb 11;101(6):e28787. doi: 10.1097/MD.0000000000028787.
10
Exploring the role and mechanism of Astragalus membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network pharmacology and experimental validation.通过网络药理学和实验验证探索黄芪和赤芍在特发性肺纤维化中的作用和机制。
Sci Rep. 2023 Sep 4;13(1):10110. doi: 10.1038/s41598-023-36944-1.

本文引用的文献

1
Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach.通过生物信息学和分子对接方法鉴定和验证獐牙菜苦苷治疗特发性肺纤维化的作用靶点。
BMC Complement Med Ther. 2023 Oct 5;23(1):352. doi: 10.1186/s12906-023-04171-w.